Get Our Top Trade Ideas Delivered Daily - 65% Off Now'
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now'
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Leerink
Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy
6 Gene Therapy M&A Targets On The Radar
Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'
6 Gene Therapy M&A Targets On The Radar
Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'
Leerink Out Bullish On GW Pharma: 4 Reasons Why
Leerink: Improving Fundamentals Drive Teva Upgrade
Leerink Out Bullish On GW Pharma: 4 Reasons Why
Leerink: Improving Fundamentals Drive Teva Upgrade
Leerink Upgrades Mednax On Margin Expansion, Share Gains And Valuation
Leerink: Translate Bio's Cystic Fibrosis Candidate Could Generate $1.8B
Read More...
Leerink Recent News
Wall Street Analysts Reflect On AT&T-Time Warner Ruling, Assess Implications Outside Tech, Media
Analysts Roar Praise For Aslan, But Leerink More Tepid
Leerink Downgrades Hologic After 'Lower Quality' Q2 Revenue Beat
Leerink Upgrades Mylan On Barrage Of Catalysts, Diversified Platforms
Leerink's Takeaways From CNBC's 'Healthy Returns' Conference
Leerin: Armo Biosciences' 'Promising' Data Justifies A Bullish Stance
Why Leerink Adjusted Upside Expectations For 3 Biotechs
AbbVie Shares Double In A Year; Leerink Moves To Sidelines
Leerink: Bluebird Bio's Catalysts Are Priced In
The CVS-Aetna Deal: The Sell Side Responds
Neurocrine Biosciences Exceeds Expectations With Ingrezza Launch
Buy Thermo Fisher On Amazon Fear-Inspired Dip
Express Scripts: Another Potential Amazon Victim?
Amazon Could Partner With UnitedHealth For Pharmacy Unit By Thanksgiving
Analyst: Amazon's Entry Into Pharmacy Is All But Certain At This Point
Selling The News In Acadia Pharmaceuticals
Pros And Cons Of All The News Out Of Acadia Pharma This Week
There's Good Cause To Be Excited About Amicus Therapeutics Clinical Program
What's The Thesis On ProQR Now, After Promising Phase 1 Data?
43% Upside Seen For Dova Pharma Following Competitor Product's Poor Results
The Street Has Finally Recognized The Exelixis Clinical Program Potential
Mirati Therapeutics Sitravatinib Data, Explained
Inside Align Technology's Q2 Beat And Raise: Teen Segment Could See An Inflection Point